Item 8.01 Other Events.

On June 23, 2020, Translate Bio, Inc. (the "Company") filed a Current Report on Form 8-Kregarding its entry into (i) a Second Amendment to the Collaboration and License Agreement, dated June 22, 2020 (the "Amendment"), with Sanofi Pasteur Inc. ("Sanofi Pasteur") and (ii) a related Securities Purchase Agreement, dated June 22, 2020 (the "Securities Purchase Agreement"), with Sanofi, a French corporation and affiliate of Sanofi Pasteur (the "Investor").

The effectiveness of the Amendment and closing of the transactions contemplated by the Securities Purchase Agreement were subject to the early termination or expiration of any applicable waiting periods under the Hart-Scott-Rodino Act Antitrust Improvements Act of 1976, as amended (the "HSR Act"), and the satisfaction or waiver of other customary closing conditions. On July 15, 2020, the Company received notice that the Federal Trade Commission granted early termination of the waiting period under the HSR Act with respect to the transactions contemplated by the Amendment and the Securities Purchase Agreement.

The Amendment became effective on July 20, 2020. On July 20, 2020, the Company completed the sale to the Investor of 4,884,434 shares of the Company's common stock at a price of $25.59 per share, for an aggregate purchase price of approximately $125.0 million in cash, pursuant to the Securities Purchase Agreement. In addition, as previously disclosed, the Company and the Investor entered into a Registration Rights Agreement at the closing of the transactions contemplated by the Securities Purchase Agreement.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses